TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice
The combination of TAS-102 and bevacizumab resulted in a better survival outcome than TAS-102 monotherapy, consistent with previous studies. This analysis supports the use of the combination of TAS-102 and bevacizumab as the best therapeutic option for patients with refractory metastatic colorectal cancer in clinical practice.
Authors
- Ho Yeong Lim (ORCID: https://orcid.org/0000-0001-9325-2300)
- Jeeyun Lee (ORCID: https://orcid.org/0000-0002-4911-6165)
- Sung Hee Lim (ORCID: https://orcid.org/0000-0001-9369-597X)
- Hana Kim (ORCID: https://orcid.org/0000-0003-2374-5200)
- Young Suk Park (ORCID: https://orcid.org/0000-0002-2900-0421)
- Ji Eun Shin (ORCID: https://orcid.org/0000-0003-1173-8142)
Institutions
- Samsung Medical Center (KR)
- The Catholic University of Korea St. Vincent's Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-30
- DOI
- https://doi.org/10.3389/fonc.2024.1450732
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00